ADAP
Adaptimmune Therapeutics
ADAP
ADAP
47 hedge funds and large institutions have $260M invested in Adaptimmune Therapeutics in 2016 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 14 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
less funds holding
Funds holding: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
29% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 14
Holders
47
Holding in Top 10
2
Calls
–
Puts
–
Top Buyers
| 1 | +$3.26M | |
| 2 | +$2.33M | |
| 3 | +$2.04M | |
| 4 |
AC
Ascend Capital
Orinda,
California
|
+$1.34M |
| 5 |
NLVP
New Leaf Venture Partners
New York
|
+$1.03M |
Top Sellers
| 1 | -$5.76M | |
| 2 | -$1.97M | |
| 3 | -$1.1M | |
| 4 |
VIA
Vident Investment Advisory
Alpharetta,
Georgia
|
-$551K |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$514K |